Burk Holdings LLC Acquires Shares of 582 Eli Lilly and Company $LLY

Burk Holdings LLC bought a new stake in Eli Lilly and Company (NYSE:LLY) during the second quarter, according to the company in its most recent disclosure with the SEC. The firm bought 582 shares of the company’s stock, valued at approximately $454,000.

A number of other institutional investors also recently modified their holdings of LLY. Wealth Preservation Advisors LLC bought a new position in Eli Lilly and Company in the first quarter valued at about $27,000. Financial Gravity Companies Inc. bought a new position in shares of Eli Lilly and Company in the second quarter worth about $31,000. Blume Capital Management Inc. boosted its stake in shares of Eli Lilly and Company by 46.7% in the 2nd quarter. Blume Capital Management Inc. now owns 44 shares of the company’s stock valued at $34,000 after purchasing an additional 14 shares in the last quarter. IMG Wealth Management Inc. bought a new stake in shares of Eli Lilly and Company during the 2nd quarter valued at approximately $35,000. Finally, TD Capital Management LLC increased its position in Eli Lilly and Company by 129.2% during the 1st quarter. TD Capital Management LLC now owns 55 shares of the company’s stock worth $46,000 after purchasing an additional 31 shares in the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have weighed in on LLY. Truist Financial raised their target price on shares of Eli Lilly and Company from $1,038.00 to $1,182.00 and gave the company a “buy” rating in a research report on Wednesday, November 19th. Morgan Stanley increased their price target on Eli Lilly and Company from $1,090.00 to $1,171.00 and gave the company an “overweight” rating in a research note on Thursday, November 13th. Cantor Fitzgerald raised their price objective on Eli Lilly and Company from $925.00 to $985.00 and gave the company an “overweight” rating in a report on Friday, October 31st. Erste Group Bank upgraded Eli Lilly and Company from a “hold” rating to a “buy” rating in a research report on Tuesday, October 14th. Finally, CICC Research increased their target price on Eli Lilly and Company from $801.00 to $1,060.00 and gave the company a “neutral” rating in a research report on Thursday, November 13th. Three analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and seven have issued a Hold rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $1,027.95.

Eli Lilly and Company Stock Performance

Shares of Eli Lilly and Company stock opened at $1,058.05 on Monday. The company has a quick ratio of 1.00, a current ratio of 1.28 and a debt-to-equity ratio of 1.86. Eli Lilly and Company has a twelve month low of $623.78 and a twelve month high of $1,066.65. The stock has a market cap of $1.00 trillion, a price-to-earnings ratio of 69.15, a P/E/G ratio of 1.21 and a beta of 0.43. The company’s fifty day moving average is $855.89 and its 200 day moving average is $787.81.

Eli Lilly and Company (NYSE:LLY) last announced its earnings results on Thursday, October 30th. The company reported $7.02 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.42 by $0.60. The business had revenue of $17.60 billion during the quarter, compared to analyst estimates of $16.09 billion. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.Eli Lilly and Company’s revenue for the quarter was up 53.9% compared to the same quarter last year. During the same period last year, the company earned $1.18 EPS. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. Sell-side analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, December 10th. Investors of record on Friday, November 14th will be paid a $1.50 dividend. This represents a $6.00 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date of this dividend is Friday, November 14th. Eli Lilly and Company’s payout ratio is currently 29.35%.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.